1. Home
  2. ATNM vs VWAV Comparison

ATNM vs VWAV Comparison

Compare ATNM & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.20

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Logo VisionWave Holdings Inc.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$6.09

Market Cap

36.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ATNM
VWAV
Founded
2000
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
31.7M
36.4M
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
ATNM
VWAV
Price
$1.20
$6.09
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
143.3K
1.8M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
0.71
N/A
Revenue
$90,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.65
N/A
Revenue Growth
11.11
N/A
52 Week Low
$0.74
$0.26
52 Week High
$1.74
$225.00

Technical Indicators

Market Signals
Indicator
ATNM
VWAV
Relative Strength Index (RSI) 53.88 48.45
Support Level $0.96 $4.93
Resistance Level $1.27 $7.40
Average True Range (ATR) 0.08 1.18
MACD -0.01 -1.85
Stochastic Oscillator 40.48 49.29

Price Performance

Historical Comparison
ATNM
VWAV

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

Share on Social Networks: